Gt Biopharma Stock Current Liabilities
| GTBP Stock | USD 3.05 0.14 4.39% |
GT Biopharma fundamentals help investors to digest information that contributes to GT Biopharma's financial success or failures. It also enables traders to predict the movement of GTBP Stock. The fundamental analysis module provides a way to measure GT Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GT Biopharma stock.
As of 05/16/2024, Total Current Liabilities is likely to grow to about 6.9 M, while Non Current Liabilities Total is likely to drop 0.00. GTBP | Current Liabilities |
GT Biopharma Company Current Liabilities Analysis
GT Biopharma's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
GTBP Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for GT Biopharma is extremely important. It helps to project a fair market value of GTBP Stock properly, considering its historical fundamentals such as Current Liabilities. Since GT Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of GT Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of GT Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
GTBP Current Liabilities Historical Pattern
Today, most investors in GT Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various GT Biopharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of GT Biopharma current liabilities as a starting point in their analysis.
GT Biopharma Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
GTBP Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, GT Biopharma has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
GTBP Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GT Biopharma's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GT Biopharma could also be used in its relative valuation, which is a method of valuing GT Biopharma by comparing valuation metrics of similar companies.GT Biopharma is currently under evaluation in current liabilities category among related companies.
GT Biopharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of GT Biopharma from analyzing GT Biopharma's financial statements. These drivers represent accounts that assess GT Biopharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of GT Biopharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 979.7M | 4.7M | 31.6M | 28.2M | 10.3M | 9.8M | |
| Enterprise Value | 990.4M | 18.0M | 52.6M | 22.7M | 9.3M | 8.8M |
GT Biopharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, GT Biopharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to GT Biopharma's managers, analysts, and investors.Environmental | Governance | Social |
GTBP Fundamentals
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.55 | ||||
| Current Valuation | (9.5 M) | ||||
| Shares Outstanding | 1.38 M | ||||
| Shares Owned By Insiders | 10.41 % | ||||
| Shares Owned By Institutions | 90.50 % | ||||
| Number Of Shares Shorted | 5.97 K | ||||
| Price To Book | 0.62 X | ||||
| EBITDA | (13.58 M) | ||||
| Net Income | (7.6 M) | ||||
| Cash And Equivalents | 23.73 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 58 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 2.78 X | ||||
| Book Value Per Share | 5.41 X | ||||
| Cash Flow From Operations | (8.85 M) | ||||
| Short Ratio | 0.81 X | ||||
| Earnings Per Share | (5.58) X | ||||
| Target Price | 150.0 | ||||
| Beta | 0.66 | ||||
| Market Capitalization | 4.29 M | ||||
| Total Asset | 14.11 M | ||||
| Retained Earnings | (682.07 M) | ||||
| Working Capital | 7.42 M | ||||
| Net Asset | 14.11 M |
About GT Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GT Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GT Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GT Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GT Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GT Biopharma's short interest history, or implied volatility extrapolated from GT Biopharma options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out GT Biopharma Piotroski F Score and GT Biopharma Altman Z Score analysis. To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.Note that the GT Biopharma information on this page should be used as a complementary analysis to other GT Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for GTBP Stock analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is GT Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GT Biopharma. If investors know GTBP will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GT Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.58) | Return On Assets (0.55) | Return On Equity (0.79) |
The market value of GT Biopharma is measured differently than its book value, which is the value of GTBP that is recorded on the company's balance sheet. Investors also form their own opinion of GT Biopharma's value that differs from its market value or its book value, called intrinsic value, which is GT Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GT Biopharma's market value can be influenced by many factors that don't directly affect GT Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GT Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if GT Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GT Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.